- Home
- CLOV vs SUPN Comparison
CLOV vs SUPN Comparison
Compare CLOV & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLOV
- SUPN
- Stock Information
- Founded
- CLOV 2014
- SUPN 2005
- Country
- CLOV United States
- SUPN United States
- Employees
- CLOV N/A
- SUPN N/A
- Industry
- CLOV Medical Specialities
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- CLOV Health Care
- SUPN Health Care
- Exchange
- CLOV Nasdaq
- SUPN Nasdaq
- Market Cap
- CLOV 1.8B
- SUPN 1.8B
- IPO Year
- CLOV N/A
- SUPN 2012
- Fundamental
- Price
- CLOV $2.92
- SUPN $33.18
- Analyst Decision
- CLOV Strong Buy
- SUPN Hold
- Analyst Count
- CLOV 3
- SUPN 2
- Target Price
- CLOV $4.83
- SUPN $36.00
- AVG Volume (30 Days)
- CLOV 12.1M
- SUPN 790.6K
- Earning Date
- CLOV 08-05-2025
- SUPN 08-05-2025
- Dividend Yield
- CLOV N/A
- SUPN N/A
- EPS Growth
- CLOV N/A
- SUPN N/A
- EPS
- CLOV N/A
- SUPN 1.11
- Revenue
- CLOV $1,486,540,000.00
- SUPN $667,997,000.00
- Revenue This Year
- CLOV $38.62
- SUPN N/A
- Revenue Next Year
- CLOV $22.21
- SUPN $12.02
- P/E Ratio
- CLOV N/A
- SUPN $29.94
- Revenue Growth
- CLOV 15.62
- SUPN 11.82
- 52 Week Low
- CLOV $1.34
- SUPN $26.65
- 52 Week High
- CLOV $4.87
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- CLOV 48.55
- SUPN 60.49
- Support Level
- CLOV $2.54
- SUPN $31.35
- Resistance Level
- CLOV $3.28
- SUPN $33.80
- Average True Range (ATR)
- CLOV 0.17
- SUPN 0.92
- MACD
- CLOV 0.05
- SUPN 0.16
- Stochastic Oscillator
- CLOV 51.49
- SUPN 79.12
About CLOV Clover Health Investments Corp.
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.